Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy of a Roller Device Facilitating Self-massage in the Treatment of Chronic Lateral Epicondylitis (EPIROLL)

25 maj 2026 uppdaterad av: Puressentiel

Evaluation of the Analgesic and Functional Efficacy of a Roller Device Facilitating Self-massage in the Treatment of Chronic Lateral Epicondylitis

Tennis elbow, also known as lateral epicondylitis, is a pathology of the enthesis of tendons attaching near or directly on the lateral epicondyle of the humerus. Lateral epicondylitis is characterized by progressive pain localized on the outer edge of the elbow, reproduced by palpation, stretching, and/or isometric resistance contraction of the lateral epicondylar muscles. This pain may be accompanied by a deficit in muscle strength compared to the opposite side. The diagnosis is mainly clinical, although imaging tests may be considered in cases of doubt or if the pain persists despite appropriate therapeutic management. There is no specific treatment for tennis elbow that has been proven to be effective. However, starting treatment can speed up the return to sporting activities and prevent the condition from becoming chronic. This study aims to fill this gap by evaluating the effectiveness of a simple and natural treatment for the symptoms of tennis elbow: a roller equipped with a ball that facilitates self-massage with simultaneous diffusion of an essential oil-based emulsion.

Objective : To evaluate the analgesic and functional efficacy of a roller device that facilitates mechanical self-massage through the simultaneous diffusion of an emulsion composed mainly of essential oils in the treatment of chronic lateral epicondylitis.

Participants : Lateral epicondylitis lasting more than 3 months, isolated and confirmed by clinical examination and ultrasound, in subjects aged 18 years and older.

Procedures : Clinical examination to confirm the diagnosis of lateral epicondylitis (specific tests for pain on stretching and palpation, elimination of differential diagnoses), and ultrasound.

  • Assessment using the PRTEE (Patient-Rated Tennis Elbow Evaluation) questionnaire (French version).
  • Assessment using the numerical pain rating scale (0-10),
  • Assessment of the location associated with the pain.
  • Treatment instructions: 2 daily applications, morning and evening, involving mechanical friction of the epicondylar and muscular area for 2 minutes, i.e., a total of 2 x 70 roller rotations (70 roller rotations on the tendon and 70 roller rotations on the muscle) for 3 months. The same parameters will be assessed one month, two months, and three months after use of the device. Patients will be randomized to receive either an Articulations & Muscles (AM) roller or a Control (T) roller.
  • Assessment of analgesic and anti-inflammatory consumption. Each participant will be given a daily monitoring diary to record their analgesic and anti-inflammatory intake.

Studieöversikt

Detaljerad beskrivning

6.1 Type of Study

International multicenter interventional, single-blind, randomized, controlled, parallel-group study in centers with practitioners trained in diagnosis.

Randomization is achieved by dedicated software.

6.2 Primary Endpoint

  • Improvement in PRTEE questionnaire scores [10, 11, 12] before and after application of the Control roller (T) or the Joints & Muscles roller (AM) combined with simultaneous delivery of an emulsion composed notably of essential oils. An improvement of 20% [13] (minimum clinically significant threshold for epicondylitis) in the PRTEE score will be used as the success criterion.
  • Improvement of the score at 1 month, 2 months, and 3 months.

6.3 Secondary Endpoints

  • Reduction in pain assessed by a numerical rating scale (0-10).
  • Reduction in analgesic and anti-inflammatory consumption.
  • Assessment of device tolerability.

6.4 Calculation of the number of participants

The primary endpoint is clinical response, defined as a ≥ 20% reduction in the PRTEE score from baseline. For each patient, the month in which the first response is observed is assessed - month 1, month 2, or month 3. If there is no response at these three time points, the patient remains included in the analysis. The model then takes into account the fact that the patient did not respond at three months and that their clinical progression beyond that point remains unknown.

Sample size:

The power of the Cox model was evaluated based on a simulation of a response 2 times faster in the active group (10%, 15%, and 20% reduction in score at 1, 2, and 3 months versus 5%, 7%, and 10% in the control group). With 40 and 30 patients per group, we obtain a power of 0.83 and 0.72 at the 0.05 level, respectively.

The following will therefore be included:

80 patients, randomly divided into two groups: Group 1: 40 patients with Control roller (T) Group 2: 40 patients with Joints and Muscles roller (AM) and essential oil-based solution

Consultation C1 (Baseline):

  • Provision of information and signing of informed consent (see Appendix 1 and 2).
  • Verification of inclusion and exclusion criteria.
  • Assessment via PRTEE questionnaire.
  • Assessment via numerical pain rating scale (0-10).
  • Assessment of pain location.
  • Provision of treatment instructions: 2 daily applications morning and evening by mechanical self-massage of the epicondylar and muscular area for 2 minutes, i.e. 2 × 70 roller passes in total (70 on the tendon and 70 on the muscle), for 3 months (an explanatory video provided via QR code in an appendix given to patients and assessors).
  • Assessment of analgesic and anti-inflammatory consumption. A daily monitoring diary will be given to each participant to record intake.
  • Provision of 3 Rollers.

Consultation C2 (1 month):

  • Assessment via PRTEE questionnaire.
  • Assessment via numerical pain rating scale (0-10).
  • Assessment of analgesic and anti-inflammatory consumption.
  • Provision of 3 Rollers.

Consultation C3 (2 months):

  • Assessment via PRTEE questionnaire.
  • Assessment via numerical pain rating scale (0-10).
  • Assessment of analgesic and anti-inflammatory consumption.
  • Provision of 3 Rollers.

Consultation C4 (3 months):

  • Assessment via PRTEE questionnaire.
  • Assessment via numerical pain rating scale (0-10).
  • Assessment of analgesic and anti-inflammatory consumption.
  • Provision of the numerical pain rating scale, in preparation for the telephone consultation.

Optional Telephone Consultation C5 (6 months):

  • Assessment via PRTEE questionnaire.
  • Assessment via numerical pain rating scale (0-10).

Studietyp

Interventionell

Inskrivning (Beräknad)

80

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:• Lateral epicondylitis of more than 3 months' duration, isolated and confirmed by clinical and ultrasonographic examination.

  • Failure of at least one prior rehabilitation treatment.
  • No ongoing physical treatment (shockwave therapy, physiotherapy) for at least 6 weeks, including a well-conducted rehabilitation.
  • Adults aged over 18 years.

Exclusion Criteria:• Manual workers in active employment conducive to lateral epicondylitis.

  • Occupational injury.
  • Patients who have received at least one treatment with PRP (platelet-rich plasma) or any other regenerative treatment.
  • Uncontrolled inflammatory or metabolic diseases.
  • Neuropsychological disorders preventing proper completion of the protocol.
  • Age under 18 years.
  • Person unable to understand French.
  • Associated osteoarticular and neurological pathologies of the upper limb.
  • Known allergy to any component of the essential oils used.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: active roller Puressentiel with essentiel oils
Automassage with the active roller Puressentiel
Active automassage with roller Puressentiel
automassage twice a day with a non active roller Puressentiel
To evaluate the analgesic and functional efficacy of a roller device that facilitates mechanical self-massage through the simultaneous diffusion of an emulsion composed mainly of essential oils in the treatment of chronic lateral epicondylitis.
Aktiv komparator: Automassage with an empty roller Puressentiel
Active automassage with roller Puressentiel
automassage twice a day with a non active roller Puressentiel
To evaluate the analgesic and functional efficacy of a roller device that facilitates mechanical self-massage through the simultaneous diffusion of an emulsion composed mainly of essential oils in the treatment of chronic lateral epicondylitis.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PRTEE questionnaire (Patient-Rated Tennis Elbow Evaluation)
Tidsram: Improvement of the score at 1 month, 2 months, and 3 months
Change in Ptient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire scores before and after application of the Control roller (T) or the Joints & Muscles roller (AM) combined with simultaneous delivery of an emulsion composed notably of essential oils. The maximum score (worse) being 100 and the minimum sore (best) being 0. An improvement of 20% [13] (minimum clinically significant threshold for epicondylitis) in the PRTEE score will be used as the success criterion
Improvement of the score at 1 month, 2 months, and 3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain assessed by a visual numerical rating scale
Tidsram: Improvement of the score at 1 month, 2 months, and 3 months.
Reduction in pain assessed by a numerical rating scale (0-10), O being the best and 10 being the worse
Improvement of the score at 1 month, 2 months, and 3 months.
Tolerance
Tidsram: Report at 1, 2 and 3 months
Report of side effects on a diary
Report at 1, 2 and 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

28 maj 2028

Avslutad studie (Beräknad)

1 september 2028

Studieregistreringsdatum

Först inskickad

18 maj 2026

Först inskickad som uppfyllde QC-kriterierna

25 maj 2026

Första postat (Faktisk)

29 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • Puressentiel 2025-A02179-40

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera